Does levodopa accelerate Parkinson's disease?

Drugs and Aging

Volumn 14, Issue 6, 1999, Pages 399-408

  Simuni, T ^a   Stern, M B ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; FREE RADICAL; LEVODOPA;

DISEASE COURSE; DYSKINESIA; GLIA CELL; HUMAN; MOTOR DYSFUNCTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0032972263     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-199914060-00001     Document Type: Review

References (98)

1. 1. WRG Gibb AJ Lees 1989 The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease Neuropathol Appl Neurobiol 15 27 44 2542825 10.1111/j.1365-2990.1989.tb01147.x 1:STN:280:DyaL1M3mt1Cquw%3D%3D Gibb WRG, Lees AJ. The significance of the Lewy body in the diagnosis of idiopathic Parkinson’s disease. Neuropathol Appl Neurobiol 1989; 15: 27–44
2. 2. H Ehringer O Hornykiewicz 1960 Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems Wien Klin Wochenschr 38 1236 9 1:CAS:528:DyaF3MXksVarsw%3D%3D Ehringer H, Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Wien Klin Wochenschr 1960; 38: 1236–9
3. 3. Cotzias GC, Papavasiliou PS. Therapeutic studies of parkinsonian patients: long-term effects of D,L-and L-dopa. Second International Congress of Neuro-ophthalmology: 1967 Sep 19; Montreal
4. 4. GC Cotzias MH Woert Van LM Schiffer 1967 Aromatic amino acids and modifications of parkinsonism N Engl J Med 276 374 9 5334614 10.1056/NEJM196702162760703 1:CAS:528:DyaF2sXnsVymsQ%3D%3D Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modifications of parkinsonism. N Engl J Med 1967; 276: 374–9
5. 5. GC Cotzias 1969 Metabolic modification of some neurologic disorders JAMA 210 1255 62 5394649 10.1001/jama.1969.03160330055011 1:STN:280:DyaE3c%2FislCnsw%3D%3D Cotzias GC. Metabolic modification of some neurologic disorders. JAMA 1969; 210: 1255–62
6. 6. CD Marsden PE Barry JD Parkes 1973 Treatment of Parkinson’s disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxy lase J Neurol Neurosurg Psychiatry 36 10 4 4691682 10.1136/jnnp.36.1.10 1:STN:280:DyaE3s7ktVGktA%3D%3D Marsden CD, Barry PE, Parkes JD, et al. Treatment of Parkinson’s disease with levodopa combined with L-alpha-methyldopahydrazine, an inhibitor of extracerebral DOPA decarboxy lase. J Neurol Neurosurg Psychiatry 1973; 36: 10–4
7. 7. CH Markham SG Diamond LJ Treciokas 1974 Carbidopa in Parkinson’s disease and in nausea and vomiting of levodopa Arch Neurol 31 3 128 33 4834974 10.1001/archneur.1974.00490380076010 1:STN:280:DyaE2c3msVWqtg%3D%3D Markham CH, Diamond SG, Treciokas LJ. Carbidopa in Parkinson’s disease and in nausea and vomiting of levodopa. Arch Neurol 1974; 31(3): 128–33
8. 8. WE Martin ES Tolosa RB Loewenson 1975 The effects of combining carbidopa with levodopa for Parkinson’s disease Genetics 30 39 44 1:STN:280:DyaE28%2FmslSjsQ%3D%3D Martin WE, Tolosa ES, Loewenson RB, et al. The effects of combining carbidopa with levodopa for Parkinson’s disease. Genetics 1975; 30: 39–44
9. 9. A Barbeau 1973 Treatment of Parkinson’s disease with L-DOPA and Ro 4-4602: review and present status MD Yahr Treatment of parkinsonism: the role of dopa decarboxylase inhibitors Raven Press New York 173 98 Barbeau A. Treatment of Parkinson’s disease with L-DOPA and Ro 4-4602: review and present status. In: Yahr MD, editor. Treatment of parkinsonism: the role of dopa decarboxylase inhibitors. New York: Raven Press, 1973: 173–98
10. 10. S Fahn 1992 Adverse effects of levodopa CW Olanow AN Lieberman The scientific basis for the treatment of Parkinson’s disease Parthenon Carnforth 89 122 Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, editors. The scientific basis for the treatment of Parkinson’s disease. Carnforth: Parthenon, 1992: 89–122
11. 11. S Fahn 1996 Is levodopa toxic? Neurology 47 Suppl.3 S184 95 8959987 10.1212/WNL.47.6_Suppl_3.184S 1:STN:280:DyaK2s7hvFWltg%3D%3D Fahn S. Is levodopa toxic? Neurology 1996; 47Suppl. 3: S184–95
12. 12. Y Agid 1998 Levodopa: is toxicity a myth? Neurology 50 858 63 9566363 10.1212/WNL.50.4.858 1:CAS:528:DyaK1cXivVajtrk%3D Agid Y. Levodopa: is toxicity a myth? Neurology 1998; 50: 858–63
13. 13. J Blin AM Bonnet Y Agid 1988 Does levodopa aggravate Parkinson’s disease? Neurology 38 1410 6 3412589 10.1212/WNL.38.9.1410 1:STN:280:DyaL1czhvFejtg%3D%3D Blin J, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson’s disease? Neurology 1988; 38: 1410–6
14. 14. G Cohen 1983 The pathobiology of Parkinson’s disease: biochemical aspects of dopamine neuron senescence J Neural Transm 89 103 Cohen G. The pathobiology of Parkinson’s disease: biochemical aspects of dopamine neuron senescence. J Neural Transm 1983; Suppl. 19: 89–103
15. 15. DMA Mann PO Yates 1983 Possible role of neuromelanin in the pathogenesis of Parkinson’s disease Mech Ageing Dev 21 193 203 6865505 10.1016/0047-6374(83)90074-X 1:CAS:528:DyaL3sXkt1Smu7k%3D Mann DMA, Yates PO. Possible role of neuromelanin in the pathogenesis of Parkinson’s disease. Mech Ageing Dev 1983; 21: 193–203
16. 16. DG Graham 1978 Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones Mol Pharmacol 14 633 43 98706 1:CAS:528:DyaE1cXlsF2is7w%3D Graham DG. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 1978; 14: 633–43
17. 17. S Fahn 1989 The endogenous toxin hypothesis of the etiology of Parkinson’s disease and a pilot trial of high dosage antioxidants in an attempt to slow the progression of the illness Ann N Y Acad Sci 570 186 96 2698103 10.1111/j.1749-6632.1989.tb14919.x 1:STN:280:DyaK3c7ps1yltg%3D%3D Fahn S. The endogenous toxin hypothesis of the etiology of Parkinson’s disease and a pilot trial of high dosage antioxidants in an attempt to slow the progression of the illness. Ann N Y Acad Sci 1989; 570: 186–96
18. 18. CW Olanow 1990 Oxidation reactions in Parkinson’s disease Neurology 40 Suppl.13 32 7 2215972 Olanow CW. Oxidation reactions in Parkinson’s disease. Neurology 1990; 40:Suppl. 13: 32–7
19. 19. P Jenner 1991 Oxidative stress as acause of Parkinson’s disease Acta Neurol Scand Suppl 136 6 15 1801537 10.1111/j.1600-0404.1991.tb05013.x 1:STN:280:DyaK387pslarug%3D%3D Jenner P. Oxidative stress as acause of Parkinson’s disease. Acta Neurol Scand Suppl 1991; 136: 6–15
20. 20. S Fahn G Cohen 1992 The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it Ann Neurol 32 804 12 1471873 10.1002/ana.410320616 1:STN:280:DyaK3s7htFOjtQ%3D%3D Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson’s disease: evidence supporting it. Ann Neurol 1992; 32: 804–12
21. 21. C Mytilineou S-K Han G Cohen 1993 Toxic and protective effects of L-DOPA on mesencepahlic cell cultures J Neurochem 61 1470 8 8376999 10.1111/j.1471-4159.1993.tb13642.x 1:CAS:528:DyaK3sXms1ans7g%3D Mytilineou C, Han S-K, Cohen G. Toxic and protective effects of L-DOPA on mesencepahlic cell cultures. J Neurochem 1993; 61: 1470–8
22. 22. MB Spina G Cohen 1988 Exposure of striatal synaptosomes to l-dopa elevates levels of oxidated glutathione J Pharmacol Exp Ther 247 502 7 3183949 1:CAS:528:DyaL1MXhvVygug%3D%3D Spina MB, Cohen G. Exposure of striatal synaptosomes to l-dopa elevates levels of oxidated glutathione. J Pharmacol Exp Ther 1988; 247: 502–7
23. 23. T Spencer Smith WD Parker Jr JP Bennett 1994 L-DOPA increases nigral productions of hydroxyl radicals in vivo: potential L-DOPA toxicity? Neuroreport 5 1009 11 10.1097/00001756-199404000-00039 Spencer Smith T, Parker Jr WD, Bennett JP. L-DOPA increases nigral productions of hydroxyl radicals in vivo: potential L-DOPA toxicity? Neuroreport 1994; 5: 1009–11
24. 24. JPE Spencer A Jenner OI Aruoma 1994 Intense oxidative DNA damage promoted by L-DOPA and its metabolites: implications for neurodegenerative disease FEBS Lett 353 246 50 7957867 10.1016/0014-5793(94)01056-0 1:CAS:528:DyaK2MXitlWqtLk%3D Spencer JPE, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-DOPA and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994; 353: 246–50
25. 25. DC Poskanzer RS Schwab 1963 Cohort analysis of Parkinson’s syndrome: evidence for a single etiology related to subclinical infection about 1920 J Chronic Dis 16 961 73 14066517 10.1016/0021-9681(63)90098-5 1:STN:280:DyaF2c%2FisVWnuw%3D%3D Poskanzer DC, Schwab RS. Cohort analysis of Parkinson’s syndrome: evidence for a single etiology related to subclinical infection about 1920. J Chronic Dis 1963; 16: 961–73
26. 26. CD Ward RC Duviosin SE Ince 1983 Parkinson’s disease in 65 pairs of twins and in a set of quadruplets Neurology 33 815 24 6683366 10.1212/WNL.33.7.815 1:STN:280:DyaL3s3ksFegtQ%3D%3D Ward CD, Duviosin RC, Ince SE, et al. Parkinson’s disease in 65 pairs of twins and in a set of quadruplets. Neurology 1983; 33: 815–24
27. 27. WG Johnson SE Hodge R Duvoisin 1990 Twin studies and the genetics of Parkinson’s disease: areappraisal MovDisord 5 187 94 10.1002/mds.870050302 1:STN:280:DyaK3czls1Sgsg%3D%3D Johnson WG, Hodge SE, Duvoisin R. Twin studies and the genetics of Parkinson’s disease: areappraisal. MovDisord 1990; 5: 187–94
28. 28. AH Rajput KP Offord CM Beard 1984 Epidemiology of parkinsonism: incidence, classification, and morality Ann Neurol 16 278 82 6333204 10.1002/ana.410160303 1:STN:280:DyaL2M%2FitFWrtQ%3D%3D Rajput AH, Offord KP, Beard CM, et al. Epidemiology of parkinsonism: incidence, classification, and morality. Ann Neurol 1984; 16: 278–82
29. 29. CM Tanner B Chen W-Z Wang 1987 Environmental factors in the etiology of Parkinson’s disease Can J Neurol Sci 14 419 23 3315147 1:STN:280:DyaL1c%2Flt1arsg%3D%3D Tanner CM, Chen B, Wang W-Z, et al. Environmental factors in the etiology of Parkinson’s disease. Can J Neurol Sci 1987; 14: 419–23
30. 30. M Stern E Dulaney SB Gruber 1991 The epidemiology of Parkinson’s disease: a case-control study of young-onset and old-onset patients Arch Neurol 48 903 7 1953412 10.1001/archneur.1991.00530210029018 1:STN:280:DyaK38%2FmtFKgsQ%3D%3D Stern M, Dulaney E, Gruber SB, et al. The epidemiology of Parkinson’s disease: a case-control study of young-onset and old-onset patients. Arch Neurol 1991; 48: 903–7
31. 31. DB Calne JW Langstem 1983 Aetiology of Parkinson’s disease Lancet II 1457 9 10.1016/S0140-6736(83)90802-4 Calne DB, Langstem JW. Aetiology of Parkinson’s disease. Lancet 1983; II: 1457–9
32. 32. P Jenner AHV Shapira CD Marsden 1992 New insights into the cause of Parkinson’s disease Neurology 42 2241 50 1461374 10.1212/WNL.42.12.2241 1:CAS:528:DyaK3sXhvVyktrs%3D Jenner P, Shapira AHV, Marsden CD. New insights into the cause of Parkinson’s disease. Neurology 1992; 42: 2241–50
33. 33. BN Ames MK Shigenaga TM Hagen 1993 Oxidants, antioxidants, and the degenerative diseases of aging Proc Natl Acad Sci USA 90 7915 22 8367443 10.1073/pnas.90.17.7915 1:CAS:528:DyaK3sXmtVSksL4%3D Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993; 90: 7915–22
34. 34. NA Simonian JT Coyle 1996 Oxidative stress in neurodegenerative diseases Ann Rev Pharmacol Toxicol 36 83 106 10.1146/annurev.pa.36.040196.000503 1:CAS:528:DyaK28Xis1ertLk%3D Simonian NA, Coyle JT. Oxidative stress in neurodegenerative diseases. Ann Rev Pharmacol Toxicol 1996; 36: 83–106
35. 35. CE Cross 1987 Oxygen radicals and human disease Ann Intern Med 107 526 45 3307585 1:STN:280:DyaL2szisVGlsQ%3D%3D Cross CE. Oxygen radicals and human disease. Ann Intern Med 1987; 107: 526–45
36. 36. PA Southorn G Powis 1988 Free radicals in medicine: 1. Chemical nature and biological reactions Mayo Clin Proc 63 381 9 2832662 1:CAS:528:DyaL1cXitFOrsb4%3D Southorn PA, Powis G. Free radicals in medicine: 1. Chemical nature and biological reactions. Mayo Clin Proc 1988; 63: 381–9
37. 37. L Oreland 1991 Monoamine oxidase, dopamine and Parkinson’s disease Acta Neurol Scand 81 Suppl.136 60 5 10.1111/j.1600-0404.1991.tb05021.x Oreland L. Monoamine oxidase, dopamine and Parkinson’s disease. Acta Neurol Scand 1991; 81Suppl. 136: 60–5
38. 38. CW Olanow MHB Youdim 1996 Iron and neurodegeneration: prospects for neuroprotection CW Olanow P Jenner MHB Youdim Neurodegeneration and neuroprotection in Parkinson’s disease Academic Press London 55 67 10.1016/B978-012525445-8/50006-0 Olanow CW, Youdim MHB. Iron and neurodegeneration: prospects for neuroprotection. In: Olanow CW, Jenner P, Youdim MHB, editors. Neurodegeneration and neuroprotection in Parkinson’s disease. London: Academic Press, 1996: 55–67
39. 39. DG Graham 1979 On the origin and significance of neuromelanin Arch Pathol Lab Med 103 359 62 582279 1:CAS:528:DyaE1MXltVGqtrs%3D Graham DG. On the origin and significance of neuromelanin. Arch Pathol Lab Med 1979; 103: 359–62
40. 40. MBH Youdim D Ben-Schachar P Riederer 1989 Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand 80 Suppl.126 47 54 10.1111/j.1600-0404.1989.tb01782.x Youdim MBH, Ben-Schachar D, Riederer P. Is Parkinson’s disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand 1989; 80Suppl. 126: 47–54
41. 41. TL Perry DV Godin S Hansen 1982 Parkinson’s disease: a disorder due to nigral glutathione deficiency Neurosci lett 33 305 10 7162692 10.1016/0304-3940(82)90390-1 1:STN:280:DyaL3s7kt1aktA%3D%3D Perry TL, Godin DV, Hansen S. Parkinson’s disease: a disorder due to nigral glutathione deficiency. Neurosci lett 1982; 33: 305–10
42. 42. E Sofic KW Lange K Jellinger 1992 Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease Neurosci Lett 142 128 30 1454205 10.1016/0304-3940(92)90355-B 1:CAS:528:DyaK38XmtFSju7w%3D Sofic E, Lange KW, Jellinger K, et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson’s disease. Neurosci Lett 1992; 142: 128–30
43. 43. J Sian DT Dexter AJ Lees 1994 Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia Ann Neurol 36 348 55 8080242 10.1002/ana.410360305 1:STN:280:DyaK2czmtFCltg%3D%3D Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 1994; 36: 348–55
44. 44. DT Dexter J Sian S Rose 1994 Indices of oxidative stress and mitrochondrial function in individuals with incidental Lewy body disease Ann Neurol 35 38 44 8285590 10.1002/ana.410350107 1:STN:280:DyaK2c7htlGqsw%3D%3D Dexter DT, Sian J, Rose S, et al. Indices of oxidative stress and mitrochondrial function in individuals with incidental Lewy body disease. Ann Neurol 1994; 35: 38–44
45. 45. B Pardo MA Mena JG Yebenes de 1995 L-DOPA inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells J Neurochem 64 576 82 7830050 10.1046/j.1471-4159.1995.64020576.x 1:CAS:528:DyaK2MXjtFymsL8%3D Pardo B, Mena MA, de Yebenes JG. L-DOPA inhibits complex IV of the electron transport chain in catecholamine-rich human neuroblastoma NB69 cells. J Neurochem 1995; 64: 576–82
46. 46. D Ben-Shachar R Zuk Y Glinka 1995 Dopamine neurotoxicity: inhibition of mitochondrial respiration J Neurochem 64 718 23 7830065 10.1046/j.1471-4159.1995.64020718.x 1:CAS:528:DyaK2MXjtFymsbY%3D Ben-Shachar D, Zuk R, Glinka Y. Dopamine neurotoxicity: inhibition of mitochondrial respiration. J Neurochem 1995; 64: 718–23
47. 47. WJ Nicklas I Vyas RE Heikkila 1985 Inhibition of NADH-linked oxidation in brain mitochondria by MPP+, a metabolite of the neurotoxin MPTP Life Sci 36 2503 8 2861548 10.1016/0024-3205(85)90146-8 1:CAS:528:DyaL2MXks1Khsbc%3D Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by MPP+, a metabolite of the neurotoxin MPTP. Life Sci 1985; 36: 2503–8
48. 48. AH Schapira JM Cooper D Dexter 1989 Mitochondrial complex I deficiency in Parkinson’s disease Lancet I 8649 1269 10.1016/S0140-6736(89)92366-0 [letter] Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson’s disease [letter]. Lancet 1989; I(8649): 1269
49. 49. AH Schapira VM Mann JM Cooper 1990 Anatomic and disease specificity of NADH CoQ reductase (complex I) deficiency in Parkinson’s disease J Neurochem 55 2142 5 2121905 10.1111/j.1471-4159.1990.tb05809.x 1:CAS:528:DyaK3MXpvFeltw%3D%3D Schapira AH, Mann VM, Cooper JM, et al. Anatomic and disease specificity of NADH CoQ reductase (complex I) deficiency in Parkinson’s disease. J Neurochem 1990; 55: 2142–5
50. 50. AH Schapira JM Cooper D Dexter 1990 Mitochondrial complex I deficiency in Parkinson’s disease J Neurochem 54 823 7 2154550 10.1111/j.1471-4159.1990.tb02325.x 1:CAS:528:DyaK3cXhsFKiur4%3D Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 1990; 54: 823–7
51. 51. S Predborski V Jackson-Lewis U Methune 1993 Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity Ann Neurol 34 715 23 10.1002/ana.410340515 Predborski S, Jackson-Lewis V, Methune U, et al. Chronic levodopa administration alters cerebral mitochondrial respiratory chain activity. Ann Neurol 1993; 34: 715–23
52. 52. JFR Kerr AH Wyllie AR Currie 1972 Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics Br J Cancer 26 238 57 10.1038/bjc.1972.33 Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br J Cancer 1972; 26: 238–57
53. 53. H Mochizuki K Goto H Mori 1996 Histochemical detection of apoptosis in Parkinson’s disease J Neurol Sci 2 137 120 3 10.1016/0022-510X(95)00336-Z Mochizuki H, Goto K, Mori H, et al. Histochemical detection of apoptosis in Parkinson’s disease. J Neurol Sci 1996; 2(137): 120–3
54. 54. I Ziv R Zilkha-Falb D Offen 1997 Levodopa induces apoptosis in cultured neuronal cells: a possible accelerator of nigrostriatal degeneration in Parkinson’s disease Mov Disord 12 17 23 8990049 10.1002/mds.870120105 1:STN:280:DyaK2s7ksVahsQ%3D%3D Ziv I, Zilkha-Falb R, Offen D, et al. Levodopa induces apoptosis in cultured neuronal cells: a possible accelerator of nigrostriatal degeneration in Parkinson’s disease. Mov Disord 1997; 12: 17–23
55. 55. G Walkinshaw CM Waters 1995 Induction of apoptosis in catecholaminergic PC 12 cells by L-DOPA: implications for the treatment of Parkinson’s disease J Clin Invest 95 2458 64 7769091 10.1172/JCI117946 1:CAS:528:DyaK2MXmtV2ru7Y%3D Walkinshaw G, Waters CM. Induction of apoptosis in catecholaminergic PC 12 cells by L-DOPA: implications for the treatment of Parkinson’s disease. J Clin Invest 1995; 95: 2458–64
56. 56. I Ziv D Offen A Barzilay 1995 The protooncogene Bcl-2, a novel cellular protective mechanism against dopamine toxicity: possible implications for Parkinson’s disease Neurology 45 Suppl.4 A279 [abstract] Ziv I, Offen D, Barzilay A, et al. The protooncogene Bcl-2, a novel cellular protective mechanism against dopamine toxicity: possible implications for Parkinson’s disease [abstract]. Neurology 1995; 45Suppl. 4: A279
57. 57. JM Masserana L Gong H Kulaga 1996 Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system Mol Pharmacol 50 1309 15 Masserana JM, Gong L, Kulaga H, et al. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol Pharmacol 1996; 50: 1309–15
58. 58. PP Michel F Hefti 1990 Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture J Neurosci Res 26 428 35 1977925 10.1002/jnr.490260405 1:CAS:528:DyaK3cXlsVGmtrw%3D Michel PP, Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 1990; 26: 428–35
59. 59. B Pardo MA Mena S Fahn 1993 Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line Mov Discord 8 278 84 10.1002/mds.870080305 1:STN:280:DyaK3szktFGisQ%3D%3D Pardo B, Mena MA, Fahn S, et al. Ascorbic acid protects against levodopa-induced neurotoxicity on a catecholamine-rich human neuroblastoma cell line. Mov Discord 1993; 8: 278–84
60. 60. B Pardo MA Mena MJ Casarejos 1995 Toxic effects of L-dopa on mesencephalic cell cultures: protection with antioxidants Brain Res 682 133 43 7552304 10.1016/0006-8993(95)00341-M 1:CAS:528:DyaK2MXmtVymsr4%3D Pardo B, Mena MA, Casarejos MJ, et al. Toxic effects of L-dopa on mesencephalic cell cultures: protection with antioxidants. Brain Res 1995; 682: 133–43
61. 61. JM Cedarbaum 1987 Clinical pharmacokinetics of anti-parkinsonian drugs Clin Phamacokinet 13 141 78 10.2165/00003088-198713030-00002 1:CAS:528:DyaL2sXmt1yhsbY%3D Cedarbaum JM. Clinical pharmacokinetics of anti-parkinsonian drugs. Clin Phamacokinet 1987; 13: 141–78
62. 62. EW Pelton HK Kimelberg SV Shipherd 1981 Dopamine and norepinephrine uptake and metabolism by astroglial cells in culture Life Sci 28 1655 63 7242252 10.1016/0024-3205(81)90322-2 1:CAS:528:DyaL3MXhslWlur8%3D Pelton EW, Kimelberg HK, Shipherd SV, et al. Dopamine and norepinephrine uptake and metabolism by astroglial cells in culture. Life Sci 1981; 28: 1655–63
63. 63. S Desagher J Glowinski J Premont 1996 Astrocytes protect neurons from hydrogen peroxide toxicity J Neurosci 16 2553 62 8786431 1:CAS:528:DyaK28XitFKhuro%3D Desagher S, Glowinski J, Premont J. Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci 1996; 16: 2553–62
64. 64. MA Mena MJ Casarejos A Carazo 1996 Glia conditioned medium protects fetal rat midbrain neurones in culture from L-dopa toxicity Neuroreport 7 441 5 8730801 10.1097/00001756-199601310-00016 1:CAS:528:DyaK28XisVCmsro%3D Mena MA, Casarejos MJ, Carazo A, et al. Glia conditioned medium protects fetal rat midbrain neurones in culture from L-dopa toxicity. Neuroreport 1996; 7: 441–5
65. 65. SK Han C Mytilineou G Cohen 1996 L-dopa up-regulates glutathione and protects mesencephalic cultures against oxidative stress J Neurochem 66 501 10 8592119 10.1046/j.1471-4159.1996.66020501.x 1:CAS:528:DyaK28XnsFCmuw%3D%3D Han SK, Mytilineou C, Cohen G. L-dopa up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996; 66: 501–10
66. 66. MA Mena V Davila D Sulzer 1997 Neurotrophic effects of L-dopa in postnatal midbrain dopamine/cortical astrocyte cocultures J Neurochem 69 1398 408 9326268 10.1046/j.1471-4159.1997.69041398.x 1:CAS:528:DyaK2sXmsVCks70%3D Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-dopa in postnatal midbrain dopamine/cortical astrocyte cocultures. J Neurochem 1997; 69: 1398–408
67. 67. TL Perry VW Yong M Ito 1984 Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically J Neurochem 43 990 3 6147392 10.1111/j.1471-4159.1984.tb12834.x 1:CAS:528:DyaL2cXlvVClur4%3D Perry TL, Yong VW, Ito M, et al. Nigrostriatal dopaminergic neurons remain undamaged in rats given high doses of L-DOPA and carbidopa chronically. J Neurochem 1984; 43: 990–3
68. 68. GC Cotzias ST Miller LC Tang 1977 Levodopa, fertility, and longevity Science 196 549 51 850799 10.1126/science.850799 1:CAS:528:DyaE2sXks1amt78%3D Cotzias GC, Miller ST, Tang LC, et al. Levodopa, fertility, and longevity. Science 1977; 196: 549–51
69. 69. F Hefti E Melamed J Bhawan 1981 Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse Neurology 31 1194 5 10.1212/WNL.31.9.1194 1:CAS:528:DyaL3MXls1aiurY%3D Hefti F, Melamed E, Bhawan J, et al. Long-term administration of L-DOPA does not damage dopaminergic neurons in the mouse. Neurology 1981; 31: 1194–5
70. 70. E Melemed J Rosenthal 1990 Can chronic levodopa therapy accelerate degeneration of dopaminergic neurons and progression of Parkinson’s disease? T Nagtsu A Fisher M Yoshida Basic, clinical, and therapeutic aspects of Alzheimer’s and Parkinson’s diseases Plenum Press New York 253 6 10.1007/978-1-4684-5844-2_49 Melemed E, Rosenthal J. Can chronic levodopa therapy accelerate degeneration of dopaminergic neurons and progression of Parkinson’s disease? In: Nagtsu T, Fisher A, Yoshida M, editors. Basic, clinical, and therapeutic aspects of Alzheimer’s and Parkinson’s diseases. New York: Plenum Press, 1990: 253–6
71. 71. DA Loeffler AJ DeMaggio PL Juneau 1994 Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation Clin Neuropharmacol 17 370 9 9316685 10.1097/00002826-199408000-00009 1:STN:280:DyaK2svmt1CnsA%3D%3D Loeffler DA, DeMaggio AJ, Juneau PL, et al. Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation. Clin Neuropharmacol 1994; 17: 370–9
72. 72. K Steece-Collier DM Yurek TJ Collier 1990 Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons Exp Neurol 110 201 8 2226699 10.1016/0014-4886(90)90031-M 1:CAS:528:DyaK3MXhtF2ltL0%3D Steece-Collier K, Yurek DM, Collier TJ, et al. Chronic levodopa impairs morphological development of grafted embryonic dopamine neurons. Exp Neurol 1990; 110: 201–8
73. 73. K Steece-Collier DM Yurek TJ Collier 1995 The detrimental effect of levodopa on behavioral efficacy of fetal dopamine neuron grafts in rats is reversible following prolonged withdraw of chronic dosing Brain Res 676 404 8 7614013 10.1016/0006-8993(95)00149-K 1:CAS:528:DyaK2MXkvFGmtrg%3D Steece-Collier K, Yurek DM, Collier TJ, et al. The detrimental effect of levodopa on behavioral efficacy of fetal dopamine neuron grafts in rats is reversible following prolonged withdraw of chronic dosing. Brain Res 1995; 676: 404–8
74. 74. SB Blunt P Jenner CD Marsden 1993 Suppressive effect of L-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine Mov Disord 8 129 33 8097279 10.1002/mds.870080202 1:STN:280:DyaK3s3jtlKrtQ%3D%3D Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-DOPA on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxydopamine. Mov Disord 1993; 8: 129–33
75. 75. MG Murer G Dziwczapolsik LB Menalled 1998 Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery in rats with moderate nigrostriatal lesions Ann Neurol 43 561 75 9585350 10.1002/ana.410430504 1:CAS:528:DyaK1cXjtFWls7k%3D Murer MG, Dziwczapolsik G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery in rats with moderate nigrostriatal lesions. Ann Neurol 1998; 43: 561–75
76. 76. N Quinn D Parkes J Janoto 1986 Preservation of the substantia nigra and locus ceruleus in a patient receiving levodopa plus decarboxylase inhibitor over a four-year period Mov Disord 1 65 8 3504233 10.1002/mds.870010109 1:STN:280:DyaL1M%2Fls12nsg%3D%3D Quinn N, Parkes D, Janoto J, et al. Preservation of the substantia nigra and locus ceruleus in a patient receiving levodopa plus decarboxylase inhibitor over a four-year period. Mov Disord 1986; 1: 65–8
77. 77. AH Rajput ME Fenton A Dhand 1996 Is levodopa toxic to nondegenerating substantia nigra cells? Clinical evidence Neurology A371 [abstract] Rajput AH, Fenton ME, Dhand A. Is levodopa toxic to nondegenerating substantia nigra cells? Clinical evidence [abstract]. Neurology 1996; 46 Suppl.: A371
78. 78. AH Rajput ME Fenton S Birdi 1997 Is levodopa toxic to human substantia nigra? Mov Disord 12 634 8 9380042 10.1002/mds.870120503 1:STN:280:DyaK1c%2FhslGgtQ%3D%3D Rajput AH, Fenton ME, Birdi S, et al. Is levodopa toxic to human substantia nigra? Mov Disord 1997; 12: 634–8
79. 79. MD Yahr A Wolf JL Antunes 1970 Autopsy findings in parkinsonism following treatment with levodopa Neurology 55 6 Yahr MD, Wolf A, Antunes JL, et al. Autopsy findings in parkinsonism following treatment with levodopa. Neurology 1970; 6 Suppl.: 55–6
80. 80. MM Hoehn MD Yahr 1967 Parkinsonism: onset, progression, and mortality Neurology 17 427 42 6067254 10.1212/WNL.17.5.427 1:STN:280:DyaF2s7jvFSgsg%3D%3D Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427–42
81. 81. MD Yahr 1976 Evaluation of long-term therapy in Parkinson’s disease: mortality and therapeutic efficacy W Birkmayer O Hornykiewicz Advances in parkinsonism Editiones Roche Basel 444 5 Yahr MD. Evaluation of long-term therapy in Parkinson’s disease: mortality and therapeutic efficacy. In: Birkmayer W, Hornykiewicz O, editors. Advances in parkinsonism. Basel: Editiones Roche, 1976: 444–5
82. 82. MMM Hoehn 1983 Parkinsonism treated with levodopa: progression and mortality J Neural Transm 253 64 Hoehn MMM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983; 19 Suppl.: 253–64
83. 83. G Scigliano M Musicco P Soliveri 1990 Mortality associated with early and late levodopa therapy initiation in Parkinson’s disease Neurology 40 265 9 2300246 10.1212/WNL.40.2.265 1:STN:280:DyaK3c7jslaktg%3D%3D Scigliano G, Musicco M, Soliveri P, et al. Mortality associated with early and late levodopa therapy initiation in Parkinson’s disease. Neurology 1990; 40: 265–9
84. 84. CE Clarke 1995 Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence Mov Disord 10 250 6 7651439 10.1002/mds.870100303 1:STN:280:DyaK2MznvFylug%3D%3D Clarke CE. Does levodopa therapy delay death in Parkinson’s disease? A review of the evidence. Mov Disord 1995; 10: 250–6
85. 85. ED Louis K Marder L Cote 1996 Age at death is significantly younger in patients with Parkinson’s disease who have dementia and severe extrapyramidal signs Neurology 46 A377 10.1212/WNL.46.5.1200 [abstract] Louis ED, Marder K, Cote L, et al. Age at death is significantly younger in patients with Parkinson’s disease who have dementia and severe extrapyramidal signs [abstract]. Neurology 1996; 46: A377
86. 86. JH Kordower TB Freeman BJ Snow 1995 Neuropathological evidence of graft survival and striatal reinnvervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease N Engl J Med 332 1118 24 7700284 10.1056/NEJM199504273321702 1:STN:280:DyaK2M3hsVKktQ%3D%3D Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnvervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson’s disease. N Engl J Med 1995; 332: 1118–24
87. 87. CH Waters 1997 Managing the late complications of Parkinson’s disease Neurology 49 Suppl.1 S49 57 9222274 10.1212/WNL.49.1_Suppl_1.S49 1:STN:280:DyaK2szmsFCntQ%3D%3D Waters CH. Managing the late complications of Parkinson’s disease. Neurology 1997; 49Suppl. 1: S49–57
88. 88. RP Lesser S Fahn SR Snider 1979 Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy Neurology 29 1253 60 573405 10.1212/WNL.29.9_Part_1.1253 1:STN:280:DyaL3c%2Fht1Sisg%3D%3D Lesser RP, Fahn S, Snider SR, et al. Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 1979; 29: 1253–60
89. 89. CW Olanow 1992 Arationale for dopamine agonists as primary therapy for Parkinson’s disease Can J Neurol Sci 19 108 12 1349262 1:STN:280:DyaK383ktVGjsA%3D%3D Olanow CW. Arationale for dopamine agonists as primary therapy for Parkinson’s disease. Can J Neurol Sci 1992; 19: 108–12
90. 90. T Caraceni G Scigliano M Mussico 1991 The occurrence of motor fluctuations in parkinsonian patients treated long-term with levodopa: role of early treatment and disease progression Neurology 41 380 4 2006005 10.1212/WNL.41.3.380 1:STN:280:DyaK3M7nt1Ciug%3D%3D Caraceni T, Scigliano G, Mussico M. The occurrence of motor fluctuations in parkinsonian patients treated long-term with levodopa: role of early treatment and disease progression. Neurology 1991; 41: 380–4
91. 91. MM Mouradian DE Heuser F Baronti 1990 Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson’s disease Ann Neurol 27 18 23 2301923 10.1002/ana.410270105 1:STN:280:DyaK3c7ks1Wrug%3D%3D Mouradian MM, Heuser DE, Baronti F, et al. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson’s disease. Ann Neurol 1990; 27: 18–23
92. 92. UK Rinne 1992 Dopamine agonists in the treatment of Parkinson’s disease UK Rinne N Yanagisawa Controversies in treatment of Parkinson’s disease PMSI Tokyo 49 60 Rinne UK. Dopamine agonists in the treatment of Parkinson’s disease. In: Rinne UK, Yanagisawa N, editors. Controversies in treatment of Parkinson’s disease. Tokyo: PMSI, 1992: 49–60
93. 93. DG Standaert MB Stern 1993 Update on the management of Parkinson’s disease Med Clin North Am 77 169 81 8093493 1:STN:280:DyaK3s7isV2rtg%3D%3D Standaert DG, Stern MB. Update on the management of Parkinson’s disease. Med Clin North Am 1993; 77: 169–81
94. 94. A Rascol B Guiraud-Chaumeil JL Montrastruc 1979 Long-term treatment of Parkinson’s disease with bromocriptine J Neurol Neurosurg Psychiatry 42 143 50 422961 10.1136/jnnp.42.2.143 1:STN:280:DyaE1M7jtFOmtw%3D%3D Rascol A, Guiraud-Chaumeil B, Montrastruc JL, et al. Long-term treatment of Parkinson’s disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979; 42: 143–50
95. 95. MC Kurth JW Tetrad CM Tanner 1993 Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa cabidopa in Parkinson’s disease patients with on-off fluctuations Neurology 43 1698 703 8414015 10.1212/WNL.43.9.1698 1:STN:280:DyaK2c%2FitVaruw%3D%3D Kurth MC, Tetrad JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa cabidopa in Parkinson’s disease patients with on-off fluctuations. Neurology 1993; 43: 1698–703
96. 96. E Bredberg D Nilsson K Johansson 1993 Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson’s disease Eur J Clin Pharmacol 45 117 22 8223831 10.1007/BF00315491 1:STN:280:DyaK2c%2FjvFenuw%3D%3D Bredberg E, Nilsson D, Johansson K, et al. Intraduodenal infusion of a water-based levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson’s disease. Eur J Clin Pharmacol 1993; 45: 117–22
97. 97. JW Roberts G Cora-Locatelli D Bravi 1994 Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonism patients Neurology 44 2685 8 Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonism patients. Neurology 1994; 44: 2685–8
98. 98. PT Mannisto S Kaakkola 1990 Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease Pharmacol Toxicol 66 317 23 2196554 10.1111/j.1600-0773.1990.tb00756.x 1:STN:280:DyaK3czhvFSgsQ%3D%3D Mannisto PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease. Pharmacol Toxicol 1990; 66: 317–23